Potential use of recombinant human thyrotropin in the treatment of distant metastases in patients with differentiated thyroid cancer.

OBJECTIVE In order to effectively treat differentiated thyroid cancer (DTC) with radioiodine (RAI) it is necessary to raise serum TSH levels either endogenously by thyroid hormone withdrawal (THW) or exogenously by administration of recombinant human TSH (rhTSH). The goal of this review is to present current data on the relative efficacy and side effects profile of rhTSH-aided versus THW-aided RAI therapy for the treatment of patients with distant metastases of DTC. METHODS We have searched the PubMed database for articles including the keywords "rhTSH", "thyroid cancer", and "distant metastases" published between January 1, 1996 and January 7, 2012. As references, we used clinical case series, case reports, review articles, and practical guidelines. RESULTS Exogenous stimulation of TSH is associated with better quality of life because it obviates signs and symptoms of hypothyroidism resulting from endogenous TSH stimulation. The rate of neurological complications after rhTSH and THW-aided RAI therapy for brain and spine metastases is similar. The rate of leukopenia, thrombocytopenia, xerostomia, and pulmonary fibrosis is similar after preparation for RAI treatment with rhTSH and THW. There is currently a controversy regarding RAI uptake in metastatic lesions after preparation with rhTSH versus THW, with some studies suggesting equal and some superior uptake after preparation with THW. Analysis of available retrospective studies comparing survival rates, progression free survival, and biochemical and structural response to a dosimetrically-determined dose of RAI shows similar efficacy after preparation for therapy with rhTSH and THW. CONCLUSION The rhTSH stimulation is not presently approved by the FDA as a method of preparation for adjunctive therapy with RAI in patients with metastatic DTC. Data on rhTSH compassionate use suggest that rhTSH stimulation is as equally effective as THW as a method of preparation for dosimetry-based RAI treatment in patients with RAI-avid metastatic DTC.

[1]  S. Larson,et al.  Recombinant Human TSH-Assisted Radioactive Iodine Remnant Ablation in Thyroid Cancer Patients at Intermediate to High Risk of Recurrence. , 2012 .

[2]  M. Mete,et al.  Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in the Identification of Metastasis in Differentiated Thyroid Cancer with 131I Planar Whole-Body Imaging and 124I PET , 2012, The Journal of Nuclear Medicine.

[3]  J. Jonklaas,et al.  Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin. , 2012, Thyroid : official journal of the American Thyroid Association.

[4]  M. Dietlein,et al.  Recombinant human TSH increases uptake and effective half-life of radioiodine in thyroid hormone secreting metastases of follicular thyroid cancer. , 2012, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[5]  J. Jonklaas,et al.  Age modifies the response to recombinant human thyrotropin. , 2010, Thyroid : official journal of the American Thyroid Association.

[6]  P. Rosário,et al.  Recombinant human thyrotropin in thyroid remnant ablation with 131-iodine in high-risk patients. , 2010, Thyroid : official journal of the American Thyroid Association.

[7]  T. Heusner,et al.  Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET/CT dosimetric comparisons , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  S. Larson,et al.  Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function. , 2010, Thyroid : official journal of the American Thyroid Association.

[9]  S. Vethakkan,et al.  Sudden onset of haemoptysis and hypoxia after recombinant human thyroid‐stimulating hormone use in a patient with papillary thyroid carcinoma and pulmonary metastases , 2009, Internal medicine journal.

[10]  Stephanie L. Lee,et al.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[11]  L. Ghiadoni,et al.  Enhanced proatherogenic inflammation after recombinant human TSH administration in patients monitored for thyroid cancer remnant , 2009, Clinical endocrinology.

[12]  G. Paz-Filho,et al.  Recombinant human thyrotropin in the management of thyroid disorders , 2008 .

[13]  M. Mussap,et al.  Absence of thyrotropin-induced increase in leptin levels in patients with history of differentiated thyroid carcinoma undergoing recombinant human thyrotropin testing , 2008, Journal of endocrinological investigation.

[14]  M. Schlumberger,et al.  131I Effective Half-Life and Dosimetry in Thyroid Cancer Patients , 2008, Journal of Nuclear Medicine.

[15]  L. Duntas,et al.  Review on the occasion of a decade of recombinant human TSH: prospects and novel uses. , 2008, Thyroid : official journal of the American Thyroid Association.

[16]  S. Larson,et al.  Recombinant Human TSH–Assisted Radioactive Iodine Remnant Ablation Achieves Short-Term Clinical Recurrence Rates Similar to Those of Traditional Thyroid Hormone Withdrawal , 2008, Journal of Nuclear Medicine.

[17]  D. Rubello,et al.  Age influences TSH serum levels after withdrawal of l-thyroxine or rhTSH stimulation in patients affected by differentiated thyroid cancer. , 2007, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[18]  E. Hindié,et al.  Stimulation test in the follow-up of thyroid cancer: Plasma rhTSH levels are dependent on body weight, not endogenously stimulated TSH values , 2007, Nuclear medicine communications.

[19]  A. Driedger,et al.  Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine. , 2006, Thyroid : official journal of the American Thyroid Association.

[20]  G. Karanikas,et al.  Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients , 2006, Clinical endocrinology.

[21]  Markus Luster,et al.  Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  A. Sorisky,et al.  Thyroid-stimulating hormone stimulates interleukin-6 release from 3T3-L1 adipocytes through a cAMP-protein kinase A pathway. , 2005, Obesity research.

[23]  M. Luster,et al.  rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. , 2005, Endocrine-related cancer.

[24]  O. Mundler,et al.  Lack of efficacy of recombinant human thyrotropin versus thyroid hormone withdrawal for radioiodine therapy imaging in a patient with differentiated thyroid carcinoma lung metastases. , 2004, Thyroid : official journal of the American Thyroid Association.

[25]  Michael R. Tuttle,et al.  Near-lethal respiratory failure after recombinant human thyroid-stimulating hormone use in a patient with metastatic thyroid carcinoma. , 2003, Thyroid : official journal of the American Thyroid Association.

[26]  R. Dierckx,et al.  Tumour dosimetry and response in patients with metastatic differentiated thyroid cancer using recombinant human thyrotropin before radioiodine therapy , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[27]  K. Bohuslavizki,et al.  Value of recombinant human thyrotropin in high-dose radioiodine therapy: a case report. , 2002, Journal of nuclear medicine technology.

[28]  S. Larson,et al.  Compassionate use of recombinant human thyrotropin to facilitate radioiodine therapy: case report and review of literature. , 2000, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[29]  D. Van Roost,et al.  Recombinant human thyrotropin in thyroid cancer and hypopituitarism due to sella metastasis. , 1999, Thyroid : official journal of the American Thyroid Association.

[30]  A. F. Stewart,et al.  Papillary thyroid carcinoma metastatic to the pituitary gland. , 1999, Thyroid.

[31]  B. Weintraub,et al.  Development and in vitro characterization of human recombinant thyrotropin. , 1999, Thyroid : official journal of the American Thyroid Association.

[32]  J. Garber,et al.  Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. , 1997, The New England journal of medicine.

[33]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[34]  L. Duntas,et al.  Short-term hypothyroidism after Levothyroxine-withdrawal in patients with differentiated thyroid cancer: clinical and quality of life consequences. , 2007, European journal of endocrinology.

[35]  A. Pinchera,et al.  Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH. , 2001, European journal of endocrinology.

[36]  B. Weintraub,et al.  Biological activity and metabolic clearance of a recombinant human thyrotropin produced in Chinese hamster ovary cells. , 1991, Endocrinology.